Warhound Raises $200 Million to Clone and Gene-Edit America's Working Dogs

The Texas startup conceived by Colossal's Ben Lamm and Anduril's Palmer Luckey emerged from stealth on October 22 at a reported $1.2 billion valuation to rebuild a US working dog supply that now leans heavily on Europe.

By Good Company Editorial Desk

2026-10-25

The News

Warhound, a Texas based defense technology company, emerged from stealth on October 22 with a $200 million seed round to rebuild America's domestic supply of elite working dogs for the US military, law enforcement and emergency first response teams. The company says it will produce genetically enhanced working dogs using cloning, secure biobanking and genetics technology licensed from Colossal Biosciences, paired with protective equipment, software and battlefield awareness tools from Anduril.

The company was conceived by Ben Lamm, co-founder and chief executive of Colossal Biosciences, and Palmer Luckey, founder of Anduril. It is led by chief executive David Spirk, a Marine Corps veteran who served as the first chief data officer for the Department of War, according to the launch announcement.

The seed round is backed by In-Q-Tel, Sequoia Capital, ARK Invest, Franklin Templeton, 8VC, USIT, Bob Nelsen, Breyer Capital, CAZ Investments, Neogenesis, Builders VC and Lux Capital, among others, the company said. Multiple reports put the post money valuation at $1.2 billion. Luckey holds no equity stake in Warhound, the company told USA TODAY, while Lamm, who does hold a stake, will serve on its board.

Lamm told USA TODAY that Warhound expects to raise Belgian Malinois, German Shepherds and Labrador Retrievers. The company says it will biobank America's top performing dogs, clone proven animals through Colossal's platform, and use genetic screening and editing to reduce inherited conditions that end careers early. The dogs will also wear Anduril Augments, including eye and ear protection and integration with its Eagle Eye system, the company said.

Warhound says it will operate under the guidance of the American Humane Society, which will certify its training programs and support reunification of retired dogs with their former handlers. No Warhound dog has been born yet. The company hopes its first puppies will be born in the first quarter of 2027, Lamm told USA TODAY.

"Every day, we ask dogs to put their lives on the line to protect ours," Lamm said in the announcement. "They detect explosives, protect our troops, and run toward dangers that most people are trained to run away from. Yet we're still relying on outdated approaches to breeding and training these extraordinary animals, with too many never making it through the process."

Why It Matters

This is not a companion pet launch, and that is exactly why pet industry readers should pay attention. Warhound treats the dog itself as the product, the supply chain and the technology platform at the same time. Instead of selling food, a collar or a service into an existing population of dogs, it proposes to manufacture the population, vertically integrated from genetics and biobanking through cloning, training and field equipment.

The supply problem it targets is real on the company's own numbers, and it is a procurement problem before it is a genetics problem. The military working dog program has run since the Army established the K-9 Corps in 1942, and the company says the current program includes more than 2,200 working dog teams. Yet most of those dogs are bought abroad, lead times are long, and roughly half of the animals bought never make it to service. Any operator who has watched a category depend on a shrinking imported supply, whether that is breeding stock, ingredients or finished goods, will recognize the shape of the risk.

Warhound also argues that healthier genetics should mean fewer dogs bred, fewer dogs washed out of intensive training, and longer, healthier working lives, with technologies from the program made available to all dogs, not only service dogs, according to the announcement. Whether that claim holds up will depend on oversight, published results and retirement practice, not launch language.

"Advances in biotechnology bring both opportunity and responsibility," said Alta Charo, professor emerita of law and bioethics at the University of Wisconsin, Madison, in the announcement. "What I find promising about Warhound is the opportunity to improve working dogs' health and welfare while supporting their lifesaving work."

The Numbers

$200 million: seed funding announced at launch on October 22, 2026
$1.2 billion: reported post money valuation, according to TechCrunch reporting cited by multiple outlets
Backers named by the company: In-Q-Tel, Sequoia Capital, ARK Invest, Franklin Templeton, 8VC, USIT, Bob Nelsen, Breyer Capital, CAZ Investments, Neogenesis, Builders VC and Lux Capital, among others
More than 2,200: working dog teams in the US Department of War Military Working Dog Program, according to the company
More than 80 percent: share of US military working dogs currently acquired from Europe, according to the company
Roughly 3 years: length of the acquisition and training pipeline the company cites
Less than half: share of procured dogs ultimately deemed fit for service, according to the company, which says the US must source and train roughly 200 dogs to field 100 working animals
10 percent or less: the washout rate Lamm told USA TODAY the company thinks it can reach by standardizing genetics and training, compared with about half today
First quarter of 2027: when Warhound hopes its first puppies will be born, according to Lamm in USA TODAY
0: Warhound dogs born, customers announced or prices disclosed at launch, based on the launch announcement and reporting to date

What It Means For You

If you run a breeding, training or working dog program, treat this as a competitive signal, not a curiosity. A $200 million seed at a reported unicorn valuation means well funded buyers will soon be competing for proven bloodlines, biobanking rights, trainers and veterinary genetics expertise. Review what your best dogs are worth, what records you actually own, and whether your health screening story would survive a buyer who can now pay for genomic proof.

If you build pet health or genetics products, the spillover is the opportunity. Warhound says technologies developed through its program will be made available to all dogs. That is a promise, not a product, but it points to where money wants this science to go next: inherited disease screening, hip and joint risk and cancer predisposition, first proven in a high value working population and then sold into the much larger companion market.

If you sell gear, training services or software to police, military or search and rescue buyers, note the bundle. Anduril is not selling a vest as an accessory. It is selling the dog, the handler and the autonomous system as one team, with eye and ear protection and Eagle Eye integration included. Standalone products aimed at that buyer will increasingly need to prove they fit an integrated stack, or find the civilian working dog buyers the bundle does not reach.

If you are a founder raising in animal health, study the structure honestly. This round was not funded on revenue, customers or a born product. It was funded on a named supply failure, two founders with track records in adjacent hard technology, a licensed platform that already exists at Colossal, and a chief executive hired for government credibility. Copy the clarity about the bottleneck, not the assumption that a large seed is available for genetics ambition alone.

What To Watch

First, births and survival. The first puppies are expected in early 2027. How many are born, how they develop, and what health screening results are shared publicly will be the first real test of a valuation that currently rests on a thesis.

Second, customers and contract shape. No signed customer or price was announced at launch. Watch for any Pentagon, law enforcement or first responder agreement, and for whether a canine as a service model, where a buyer pays for a steady supply of trained dogs rather than individual animals, turns into a real procurement.

Third, the washout claim in practice. Lamm's stated target is a washout rate of 10 percent or less, against about half today. That number is measurable, and Warhound should be held to it once its first cohorts enter training. If the rate does not move, the genetics case weakens fast.

Fourth, welfare oversight. The American Humane Society's certification role, the bioethics guidance the company announced, and how retired dogs are placed will draw scrutiny, especially as criticism of gene editing working animals builds. How the company answers that scrutiny, with published standards or with statements only, will shape whether the broader pet industry can borrow any of this science without inheriting the controversy.

Sources

Warhound launch announcement via PR Newswire on Morningstar, October 22, 2026: https://www.morningstar.com/news/pr-newswire/20261022da79486/warhound-launches-with-200-million-to-rebuild-americas-military-working-dog-supply-using-advanced-genetics-and-defense-technology

USA TODAY, Dire wolf genetic tech to help create warhounds, October 22, 2026: https://www.usatoday.com/story/pets-animals/dog/2026/10/22/dire-wolf-company-warhound-military-dogs-cloning/92383771007/

GREY Journal, Warhound Raises $200M to Clone and Gene-Edit America's Military Working Dogs, October 24, 2026: https://greyjournal.net/news/warhound-200-million-seed-military-working-dogs/

Dealroom News, Warhound launches with $200M seed, October 22, 2026: https://dealroom.co/news/x-2113415092444295664-warhound-launches-with-200m-seed-to-clone-and-gene-edit-us-military-work/